Academic literature on the topic 'Glenzocimab'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glenzocimab.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Glenzocimab"
Pottecher, Julien, Francois Raffi, Martine Jandrot-Perrus, Sophie Binay, Andrea Comenducci, Violaine Desort-Henin, Déborah François, et al. "Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial." PLOS ONE 19, no. 6 (June 17, 2024): e0302897. http://dx.doi.org/10.1371/journal.pone.0302897.
Full textRenaud, Lionel, Kristell Lebozec, Christine Voors‐Pette, Peter Dogterom, Philippe Billiald, Martine Jandrot Perrus, Yannick Pletan, and Matthias Machacek. "Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation." Journal of Clinical Pharmacology 60, no. 9 (June 4, 2020): 1198–208. http://dx.doi.org/10.1002/jcph.1616.
Full textJandrot-Perrus, M., J. Pottecher, E. Toledano, A. Commenducci, A. Meilhoc, S. Gharakhanian, G. Avenard, Y. Pletan, S. Binay, and M. Mazighi. "PB0364 Glycoprotein VI-Targeted Antiplatelet Therapy with Glenzocimab is Safe in Patients Exposed to Current Antithrombotic and Fibrinolytic Drugs." Research and Practice in Thrombosis and Haemostasis 7 (October 2023): 101499. http://dx.doi.org/10.1016/j.rpth.2023.101499.
Full textComenducci, Andrea, Adeline Meilhoc, Yannick Pletan, Sophie Binay, Gilles Avenard, Alistair Perry, Rafael Namias, et al. "Abstract 28: Patients Randomised to Glenzocimab Suffered Less Haemorrhagic Transformation at 24 Hours Compared to Placebo: AI-Imaging Sub-Analysis of the ACTIMIS Trial." Stroke 55, Suppl_1 (February 2024). http://dx.doi.org/10.1161/str.55.suppl_1.28.
Full textComenducci, Andrea, Adeline Meilhoc, Yannick Pletan, Sophie Binay, Gilles Avenard, Davide Carone, Alistair Perry, et al. "Abstract 006: Glenzocimab Is Associated With Less Haemorrhagic Transformation Using Artificial Intelligence Imaging In Mechanical Thrombectomy Patients." Stroke: Vascular and Interventional Neurology 3, S2 (November 2023). http://dx.doi.org/10.1161/svin.03.suppl_2.006.
Full textWichaiyo, Surasak, Warisara Parichatikanond, and Wipharak Rattanavipanon. "Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke." Stroke, September 21, 2022. http://dx.doi.org/10.1161/strokeaha.122.039790.
Full textAlenazy, F. O., M. H. Harbi, D. P. Kavanagh, J. Price, P. Brady, O. Hargreaves, P. H. Harrison, et al. "GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy." European Heart Journal 42, Supplement_1 (October 1, 2021). http://dx.doi.org/10.1093/eurheartj/ehab724.1425.
Full textBilliald, Philippe, Alexandre Slater, Martin Welin, Joanne C. Clark, Loyau Stéphane, Martine Pugnière, Isabella Gizzi Jiacomini, et al. "Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition." Blood Advances, November 14, 2022. http://dx.doi.org/10.1182/bloodadvances.2022007863.
Full textJadoui, Soumaya, Ophélie Le Chapelain, Véronique Ollivier, Ali Mostefa-Kara, Lucas Di Meglio, Sébastien Dupont, Angèle Gros, et al. "Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis." Haematologica, December 30, 2020. http://dx.doi.org/10.3324/haematol.2020.270439.
Full textAlenazy, Fawaz O., Maan H. Harbi, Dean P. Kavanagh, Joshua Price, Paul Brady, Oscar Hargreaves, Paul Harrison, et al. "Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy." Journal of Thrombosis and Haemostasis, August 2023. http://dx.doi.org/10.1016/j.jtha.2023.07.018.
Full textDissertations / Theses on the topic "Glenzocimab"
Kern, Axelle Y. "La thrombose de stent : évaluation de l’importance de la rhéologie dans la thrombogénicité des stents et d’un nouvel agent pharmacologique dirigé contre la GPVI pour prévenir la thrombose de stent." Electronic Thesis or Diss., Strasbourg, 2024. http://www.theses.fr/2024STRAJ027.
Full textA major complication of stenting in a diseased artery is stent thrombosis, which has a particularly high mortality rate. Dual antiplatelet therapy, indicated to prevent this complication, possesses a high risk of bleeding and is not always effective. The aim of my PhD was to identify the mechanisms of stent thrombosis and to evaluate the interest of a new class of antiplatelet agents to efficiently prevent it with a low bleeding risk. The development of an original macrofluidic model has enabled us to show that the carotid stents used in clinical practice present an intrinsic thrombogenicity evidenced both at the bifurcation of a vessel where the stent meshes lie in the lumen, and around some specific places of the stent struts which are in contact with the vessel wall. The device also helped to identify a protective effect of the stent mesh, which reduces stent thrombosis. Finally, the model showed that glenzocimab, an anti-GPVI agent, is effective in preventing stent thrombosis to a similar extent than reference treatments, but with no bleeding risk
Conference papers on the topic "Glenzocimab"
Pottecher, J., V. A. H. Sato, Y. Plétan, A. Comenducci, V. Desort-Henin, M. Jandrot-Perrus, S. Binay, A. Meilhoc, and G. Avenard. "A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS)." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2878.
Full textKöhrmann, Martin, Elie Toledano, Yannick Plétan, Andrea Comenducci, Adeline Meilhoc, Sophie Binay, Gilles Avenard, and James Grotta. "P024 ACTISAVE study: efficacy and safety of glenzocimab on top of thrombolysis and mechanical thrombectomy." In 16th Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT) 2024, A36.2—A36. BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd., 2024. http://dx.doi.org/10.1136/jnis-2024-esmint.61.
Full text